Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment

1 Aug 2021

Abstract excerpt

PURPOSE: Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) are important biomarkers for predicting responses to immune checkpoint inhibitor (ICI) therapies. Although PCR-based tests for high MSI (MSI-H) and dMMR yield highly concordant results in endometrial cancer (EC), it is unclear whether this is true for MSI-H and MMR detected by next-generation sequencing (NGS) and immunohistochemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Endometrial and Cervical Cancer Treatments
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34429613
DOI: 10.2147/ott.s324641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune MicroenvironmentPMID 34429613Read ↗

Traditional and New Views on MSI-H/dMMR Endometrial Cancer.Semantic proximity Read ↗

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial CancerSemantic proximity Read ↗

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancersSemantic proximity Read ↗

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilitySemantic proximity Read ↗

Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical ImplicationsSemantic proximity Read ↗

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite InstabilitySemantic proximity Read ↗

High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancerSemantic proximity Read ↗

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing DataSemantic proximity Read ↗

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudySemantic proximity Read ↗

Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial CarcinomaSemantic proximity Read ↗

Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesSemantic proximity Read ↗

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.